Skip to content

Released Nov 14, 2023, after the close

10-Q filed Nov 14, 2023, 45 days after period end · 0001785530-23-000033

Q3 2023 · 10-Q
Revenue—
Net Income-$8.29MN/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$0.23N/M vs Q3 2022N/M vs Q2 2023
Operating Income-$9,251,000N/M
Operating Cash Flowderived-$7,208,000N/M
Free Cash Flowderived-$7,429,000N/M

What the release said

The release

Same quarter

MetricQ3 2023Q3 2022Q3 2021Q3 2020
Net Income-$8.29M-$11.94M-$13.76M-$6.07M
EPS Diluted-$0.23-$0.40-$0.51-$6.61

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR